866-997-4948(US-Canada Toll Free)

Multiple Myeloma (Kahler\'s Disease) - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Oncology

No. of Pages : 471 Pages


Global Markets Directs, \'Multiple Myeloma (Kahler\'s Disease) - Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Multiple Myeloma (Kahler\'s Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler\'s Disease). Multiple Myeloma (Kahler\'s Disease) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Multiple Myeloma (Kahler\'s Disease).
  • A review of the Multiple Myeloma (Kahler\'s Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Multiple Myeloma (Kahler\'s Disease) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler\'s Disease).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler\'s Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Multiple Myeloma (Kahler\'s Disease) Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Multiple Myeloma (Kahler\'s Disease) 13
Multiple Myeloma (Kahler\'s Disease) Therapeutics under Development by Companies 15
Multiple Myeloma (Kahler\'s Disease) Therapeutics under Investigation by Universities/Institutes 22
Late Stage Products 24
Comparative Analysis 24
Mid Clinical Stage Products 25
Comparative Analysis 25
Early Clinical Stage Products 26
Comparative Analysis 26
Discovery and Pre-Clinical Stage Products 27
Comparative Analysis 27
Multiple Myeloma (Kahler\'s Disease) Therapeutics - Products under Development by Companies 28
Multiple Myeloma (Kahler\'s Disease) Therapeutics - Products under Investigation by Universities/Institutes 36
Companies Involved in Multiple Myeloma (Kahler\'s Disease) Therapeutics Development 37
Johnson & Johnson 37
F. Hoffmann-La Roche Ltd. 38
Amgen Inc. 39
Eli Lilly and Company 40
Viralytics Ltd. 41
GlaxoSmithKline plc 42
Seattle Genetics, Inc. 43
Gilead Sciences, Inc. 44
Biotest AG 45
medac GmbH 46
Merck & Co., Inc. 47
Gamida Cell Ltd. 48
BioLineRx, Ltd. 49
Amorfix Life Sciences Ltd. 50
ZIOPHARM Oncology, Inc. 51
Millennium Pharmaceuticals, Inc. 52
Novartis AG 53
Nippon Kayaku Co., Ltd. 54
Pfizer Inc. 55
Sigma-Tau S.p.A. 56
SuperGen, Inc. 57
Taiho Pharmaceutical Co., Ltd. 58
Teva Pharmaceutical Industries Limited 59
Santaris Pharma A/S 60
Aduro BioTech 61
Celgene Corporation 62
Onyx Pharmaceuticals, Inc. 63
XTL Biopharmaceuticals Ltd. 64
MannKind Corporation 65
Merck KGaA 66
4SC AG 67
EntreMed, Inc. 68
GENTIUM S.p.A. 69
AEterna Zentaris Inc. 70
ImmunoCellular Therapeutics, Ltd. 71
IMMUNOMEDICS, INC 72
Oncolytics Biotech Inc. 73
Compugen Ltd. 74
Patrys Limited 75
Curis, Inc. 76
VioQuest Pharmaceuticals, Inc. 77
BioInvent International AB 78
Choongwae Pharma Corp 79
Innate Pharma SA 80
Transgene Biotek Ltd 81
Cellerant Therapeutics, Inc. 82
Cancer Research Technology Limited 83
Spectrum Pharmaceuticals, Inc. 84
Chroma Therapeutics Ltd. 85
Abiogen Pharma S.p.A. 86
Acceleron Pharma, Inc. 87
Altor BioScience Corporation 88
Coronado Biosciences, Inc. 89
Arno Therapeutics, Inc. 90
Vaccinex, Inc. 91
CanBas Co., Ltd. 92
Axelar AB 93
Onconova Therapeutics, Inc 94
Immune System Therapeutics Ltd. 95
Concert Pharmaceuticals, Inc. 96
NOXXON Pharma AG 97
Xencor, Inc. 98
Immunocore Limited. 99
Tragara Pharmaceuticals, Inc. 100
PharmaMar, S.A. 101
KaloBios Pharmaceuticals, Inc. 102
AB Science 103
Cylene Pharmaceuticals, Inc. 104
Centocor Ortho Biotech, Inc. 105
Profectus BioSciences, Inc. 106
Elara Pharmaceuticals GmbH 107
Molecular Templates Inc. 108
Gliknik, Inc. 109
Immunovative Therapies, Ltd. 110
America Stem Cell, Inc. 111
Advancell 112
Multiple Myeloma (Kahler\'s Disease) - Therapeutics Assessment 113
Assessment by Monotherapy Products 113
Assessment by Combination Products 114
Assessment by Route of Administration 115
Assessment by Molecule Type 118
Drug Profiles 121
denosumab - Drug Profile 121
alvocidib - Drug Profile 124
ixazomib citrate - Drug Profile 125
ixazomib citrate - Drug Profile 128
pevonedistat - Drug Profile 131
tabalumab - Drug Profile 132
tabalumab - Drug Profile 134
tecemotide - Drug Profile 136
brentuximab vedotin - Drug Profile 139
acadesine - Drug Profile 143
sotatercept - Drug Profile 145
ENMD-2076 - Drug Profile 147
4SC-202 - Drug Profile 149
AT-9283 - Drug Profile 151
AT-7519 - Drug Profile 153
AR-42 - Drug Profile 155
ICT-69 - Drug Profile 157
ICT-037 - Drug Profile 159
PAT-SM6 - Drug Profile 160
MDX-1097 - Drug Profile 162
MDX-1458 - Drug Profile 163
carfilzomib - Drug Profile 164
AXL-1717 - Drug Profile 167
IPH-2101 - Drug Profile 169
TG-02 - Drug Profile 171
pelareorep - Drug Profile 172
idelalisib - Drug Profile 176
darinaparsin - Drug Profile 178
elotuzumab - Drug Profile 180
melphalan - Drug Profile 182
BT-062 - Drug Profile 183
rigosertib sodium - Drug Profile 185
NOX-A-12 - Drug Profile 188
BI-505 - Drug Profile 190
MLN-0128 - Drug Profile 191
siltuximab - Drug Profile 193
KB-004 - Drug Profile 197
CVA-21 - Drug Profile 199
dovitinib lactate - Drug Profile 203
NPI-1342 - Drug Profile 206
SST-0001 - Drug Profile 207
ABT-737 - Drug Profile 208
PM-00104 - Drug Profile 209
XmAb-5592 - Drug Profile 210
rivipansel sodium - Drug Profile 211
ImMucin - Drug Profile 213
cUV-3 - Drug Profile 214
silmitasertib - Drug Profile 215
Anti-CD3 x Anti-CD20 Bispecific Antibody Armed Activated T Cells + Autologous Peripheral Blood Stem Cell Transplantation - Drug Profile 217
vorinostat - Drug Profile 218
NK-012 - Drug Profile 222
Kappa CD28 T Cells - Drug Profile 224
treosulfan - Drug Profile 225
lenalidomide - Drug Profile 227
lenalidomide - Drug Profile 230
lenalidomide - Drug Profile 233
marizomib - Drug Profile 236
Drug For Multiple Myeloma - Drug Profile 238
masitinib - Drug Profile 239
CGEN-928 - Drug Profile 241
Allogeneic Myeloma Vaccine + Activated Marrow Infiltrating Lymphocytes - Drug Profile 242
afuresertib - Drug Profile 243
bevacizumab - Drug Profile 245
Therapeutic Tumor Infiltrating Lymphocytes - Drug Profile 249
ALT-803 - Drug Profile 250
MKC-204 - Drug Profile 252
CD4 Donor Lymphocytes - Drug Profile 253
VX-30 - Drug Profile 254
CBS-9106 - Drug Profile 255
Multiple Myeloma BiTE - Drug Profile 257
CUDC-907 - Drug Profile 258
EZN-3892 - Drug Profile 260
BHQ-880 - Drug Profile 261
CC-115 - Drug Profile 263
MRx-102 - Drug Profile 264
CWP-232291 - Drug Profile 266
CC-122 - Drug Profile 268
ImmTAC Targeting NY ESO - Drug Profile 270
afuresertib + trametinib - Drug Profile 271
CNDO-109 - Drug Profile 272
TBL-0306M - Drug Profile 274
EL-102 - Drug Profile 275
EL-103 - Drug Profile 276
MTI-101 - Drug Profile 277
FV-162 - Drug Profile 278
Cancer Stem Cell Antibody Program - Drug Profile 279
BL-8040 - Drug Profile 280
Vif-derived Peptide - Drug Profile 282
ATX-101 - Drug Profile 283
KPT-330 - Drug Profile 284
Anti-CD38 - Drug Profile 286
EL-101 - Drug Profile 287
CTP-221 - Drug Profile 288
ARC-205 - Drug Profile 289
CM-10 - Drug Profile 290
GL-0817 - Drug Profile 291
MBC-11 - Drug Profile 292
ER Stress and Autophagy Program - Drug Profile 293
ER Stress 2-Series Program - Drug Profile 294
ER Stress Program TBN - Drug Profile 295
TGR-1202 - Drug Profile 296
Anti-CD48 mAb - Drug Profile 297
TAS-2985 - Drug Profile 298
IGN-003 - Drug Profile 299
Genetically Modified T Cell - Drug Profile 300
Anti-APRIL - Drug Profile 301
Monoclonal Antibodies Against CD28 - Drug Profile 302
Monoclonal Antibody For Multiple Myeloma - Drug Profile 303
Drug For Multiple Myeloma - Drug Profile 304
IPSI-001 - Drug Profile 305
SHIP1 Inhibitors - Drug Profile 306
interferon alfa-2b biosimilar - Drug Profile 307
DNA Fusion Vaccines - Drug Profile 308
Drug Targeting MMSET/NSD2 - Drug Profile 310
Pim2 Inhibitor For Multiple Myeloma - Drug Profile 311
Drug For Multiple Myeloma - Drug Profile 312
ASC-102 - Drug Profile 313
Drug For Multiple Myeloma - Drug Profile 314
Carnitine Palmitoyltransferase-1 Inhibitor - Drug Profile 315
Lipase Inhibitor - Drug Profile 316
CR-2408 - Drug Profile 317
PBS-1086 - Drug Profile 318
First Generation Attenuated Strain Of Reovirus - Drug Profile 320
JP-11646 - Drug Profile 321
BET Bromodomain Inhibitors - Drug Profile 322
Tumor-Primed Natural Killer Cells - Drug Profile 323
Nucleoside Analogs - Drug Profile 325
Central Memory T Cell Therapy For Cancer - Drug Profile 326
Multiple Myeloma (Kahler\'s Disease) Therapeutics - Drug Profile Updates 327
Multiple Myeloma (Kahler\'s Disease) Therapeutics - Discontinued Products 450
Multiple Myeloma (Kahler\'s Disease) Therapeutics - Dormant Products 451
Multiple Myeloma (Kahler\'s Disease) - Product Development Milestones 454
Featured News & Press Releases 454

Appendix 461
Methodology 461
Coverage 461
Secondary Research 461
Primary Research 461
Expert Panel Validation 461
Contact Us 462
Disclaimer 462

List of Table


Number of Products Under Development for Multiple Myeloma (Kahler\'s Disease), H2 2013 22
Products under Development for Multiple Myeloma (Kahler\'s Disease) - Comparative Analysis, H2 2013 23
Number of Products under Development by Companies, H2 2013 25
Number of Products under Development by Companies, H2 2013 (Contd..1) 26
Number of Products under Development by Companies, H2 2013 (Contd..2) 27
Number of Products under Development by Companies, H2 2013 (Contd..3) 28
Number of Products under Development by Companies, H2 2013 (Contd..4) 29
Number of Products under Development by Companies, H2 2013 (Contd..5) 30
Number of Products under Investigation by Universities/Institutes, H2 2013 32
Comparative Analysis by Late Stage Development, H2 2013 33
Comparative Analysis by Mid Clinical Stage Development, H2 2013 34
Comparative Analysis by Early Clinical Stage Development, H2 2013 35
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 36
Products under Development by Companies, H2 2013 37
Products under Development by Companies, H2 2013 (Contd..1) 38
Products under Development by Companies, H2 2013 (Contd..2) 39
Products under Development by Companies, H2 2013 (Contd..3) 40
Products under Development by Companies, H2 2013 (Contd..4) 41
Products under Development by Companies, H2 2013 (Contd..5) 42
Products under Development by Companies, H2 2013 (Contd..6) 43
Products under Development by Companies, H2 2013 (Contd..7) 44
Products under Investigation by Universities/Institutes, H2 2013 45
Johnson & Johnson, H2 2013 46
F. Hoffmann-La Roche Ltd., H2 2013 47
Amgen Inc., H2 2013 48
Eli Lilly and Company, H2 2013 49
Viralytics Ltd., H2 2013 50
GlaxoSmithKline plc, H2 2013 51
Seattle Genetics, Inc., H2 2013 52
Gilead Sciences, Inc., H2 2013 53
Biotest AG, H2 2013 54
medac GmbH, H2 2013 55
Merck & Co., Inc., H2 2013 56
Gamida Cell Ltd., H2 2013 57
BioLineRx, Ltd., H2 2013 58
Amorfix Life Sciences Ltd., H2 2013 59
ZIOPHARM Oncology, Inc., H2 2013 60
Millennium Pharmaceuticals, Inc., H2 2013 61
Novartis AG, H2 2013 62
Nippon Kayaku Co., Ltd., H2 2013 63
Pfizer Inc., H2 2013 64
Sigma-Tau S.p.A., H2 2013 65
SuperGen, Inc., H2 2013 66
Taiho Pharmaceutical Co., Ltd., H2 2013 67
Teva Pharmaceutical Industries Limited, H2 2013 68
Santaris Pharma A/S, H2 2013 69
Aduro BioTech, H2 2013 70
Celgene Corporation, H2 2013 71
Onyx Pharmaceuticals, Inc., H2 2013 72
XTL Biopharmaceuticals Ltd., H2 2013 73
MannKind Corporation, H2 2013 74
Merck KGaA, H2 2013 75
4SC AG, H2 2013 76
EntreMed, Inc., H2 2013 77
GENTIUM S.p.A., H2 2013 78
AEterna Zentaris Inc., H2 2013 79
ImmunoCellular Therapeutics, Ltd., H2 2013 80
IMMUNOMEDICS, INC, H2 2013 81
Oncolytics Biotech Inc., H2 2013 82
Compugen Ltd., H2 2013 83
Patrys Limited, H2 2013 84
Curis, Inc., H2 2013 85
VioQuest Pharmaceuticals, Inc., H2 2013 86
BioInvent International AB, H2 2013 87
Choongwae Pharma Corp, H2 2013 88
Innate Pharma SA, H2 2013 89
Transgene Biotek Ltd, H2 2013 90
Cellerant Therapeutics, Inc., H2 2013 91
Cancer Research Technology Limited, H2 2013 92
Spectrum Pharmaceuticals, Inc., H2 2013 93
Chroma Therapeutics Ltd., H2 2013 94
Abiogen Pharma S.p.A., H2 2013 95
Acceleron Pharma, Inc., H2 2013 96
Altor BioScience Corporation, H2 2013 97
Coronado Biosciences, Inc., H2 2013 98
Arno Therapeutics, Inc., H2 2013 99
Vaccinex, Inc., H2 2013 100
CanBas Co., Ltd., H2 2013 101
Axelar AB, H2 2013 102
Onconova Therapeutics, Inc, H2 2013 103
Immune System Therapeutics Ltd., H2 2013 104
Concert Pharmaceuticals, Inc., H2 2013 105
NOXXON Pharma AG, H2 2013 106
Xencor, Inc., H2 2013 107
Immunocore Limited., H2 2013 108
Tragara Pharmaceuticals, Inc., H2 2013 109
PharmaMar, S.A., H2 2013 110
KaloBios Pharmaceuticals, Inc., H2 2013 111
AB Science, H2 2013 112
Cylene Pharmaceuticals, Inc., H2 2013 113
Centocor Ortho Biotech, Inc., H2 2013 114
Profectus BioSciences, Inc., H2 2013 115
Elara Pharmaceuticals GmbH, H2 2013 116
Molecular Templates Inc., H2 2013 117
Gliknik, Inc., H2 2013 118
Immunovative Therapies, Ltd., H2 2013 119
America Stem Cell, Inc., H2 2013 120
Advancell, H2 2013 121
Assessment by Monotherapy Products, H2 2013 122
Assessment by Combination Products, H2 2013 123
Assessment by Stage and Route of Administration, H2 2013 126
Assessment by Stage and Molecule Type, H2 2013 129
Multiple Myeloma (Kahler\'s Disease) Therapeutics - Drug Profile Updates 336
Multiple Myeloma (Kahler\'s Disease) Therapeutics - Discontinued Products 459
Multiple Myeloma (Kahler\'s Disease) Therapeutics - Dormant Products 460
Multiple Myeloma (Kahler\'s Disease) Therapeutics - Dormant Products (Contd..1) 461
Multiple Myeloma (Kahler\'s Disease) Therapeutics - Dormant Products (Contd..3) 462

List of Chart


Number of Products under Development for Multiple Myeloma (Kahler\'s Disease), H2 2013 22
Products under Development for Multiple Myeloma (Kahler\'s Disease) - Comparative Analysis, H2 2013 23
Products under Development by Companies, H2 2013 24
Products under Investigation by Universities/Institutes, H2 2013 31
Late Stage Products, H2 2013 33
Mid Clinical Stage Products, H2 2013 34
Early Clinical Stage Products, H2 2013 35
Discovery and Pre-Clinical Stage Products, H2 2013 36
Assessment by Monotherapy Products, H2 2013 122
Assessment by Combination Products, H2 2013 123
Assessment by Route of Administration, H2 2013 124
Assessment by Stage and Route of Administration, H2 2013 125
Assessment by Molecule Type, H2 2013 127
Assessment by Stage and Molecule Type, H2 2013 128

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *